RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- AlphaVax, Inc. recently received notification from the National Institute of Allergies and Infectious Diseases (NIAID), one of the granting institutes of the National Institutes of Health (NIH), that it has been awarded a second grant to continue development of a smallpox vaccine based on AlphaVax's proprietary vector platform. The grant will support additional studies in rodents and non- human primates to further characterize the high-level protection observed previously in these species.
Work completed during the first grant period demonstrated that AlphaVax's smallpox vaccine, which expresses four, highly conserved poxvirus proteins, could provide humoral responses comparable to those obtained with a licensed vaccine. Furthermore, the AlphaVax vaccine protected mice against vaccinia virus challenge and non-human primates against a lethal challenge with monkeypox virus. The details of this work will be presented by Dr. Kurt Kamrud, Director of Discovery Research at AlphaVax and the Principal Investigator on both grants, at the XVII International Poxvirus and Iridovirus Conference in Grainau, Germany on June 7-12th, 2008.
"The work completed under the NIAID grant to date is an excellent demonstration of the potential of our alphavirus vector platform to address many different diseases as well as bioterrorism threats. We have shown efficacy of this platform in numerous animal models and safety and immunogenicity in three clinical trials to date. We look forward to working with the U.S. Government to advance a new smallpox vaccine that has an excellent safety profile and is capable of being rapidly manufactured using AlphaVax's proprietary manufacturing process," said Dr. Jonathan F. Smith, Chief Scientific Officer at AlphaVax.
AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs. In addition to cytomegalovirus, important disease targets include influenza, cancer, HSV, RSV, and a number of biodefense vaccine products. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC.
About NIH Grant Support
The work described was supported by Grant Number UC1AI067183-01 from the National Institute of Allergy And Infectious Diseases. The content of this press release is solely the responsibility of AlphaVax and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institutes of Health.
CONTACT: Dr. Jonathan F. Smith of AlphaVax, Inc., +1-919-595-0397
Web site: http://www.alphavax.com/